| Literature DB >> 31443546 |
Yerim Kim1,2, Seung-Hoon Lee3,4.
Abstract
Background andEntities:
Keywords: CADASIL; NOTCH 3 protein; cerebral infarction; intracranial hemorrhage; mutation; stroke
Mesh:
Substances:
Year: 2019 PMID: 31443546 PMCID: PMC6780260 DOI: 10.3390/medicina55090521
Source DB: PubMed Journal: Medicina (Kaunas) ISSN: 1010-660X Impact factor: 2.430
Figure 1NOTCH3 gene mutations. (A) NOTCH3 gene located on chromosome 19p13.12; (B) NOTCH3 gene mutations are located within the extracellular domain that encodes the epidermal growth factor like repeats, 3 Lin-NOTCH repeats, and 1 transmembrane region; (C) NOTCH3 gene mutations or variants of unknown significances in our study. Red bold text is the most common genetic region in this study. * Novel variants of unknown significance.
Baseline characteristics of patients with known NOTCH 3 mutations or novel variants of unknown significance (VUS).
| Age/Sex | Nucleotide | Exon | Amino Acid | Risk Factors | Symptom | MRI/MRA | Location of IS | Location of HS | No. of MBs | Location of MBs | Modified Fazekas | White Matter Lesions | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 57/M | 224G>C | 3 | R75P | DL | IS | +/+ | Rt. pons | 12 | B,D,E | 3 | a1,b1,c | |
| 2 | 43/M | 224G>C | 3 | R75P | HTN, DL | IS | +/+ | Rt. MCA | 1 | A | 2 | c | |
| 3 | 43/F | 224G>C | 3 | R75P | HTN | HS | +/+ | Rt. BG | 0 | 1 | c | ||
| 4 | 56/F | 224C>T | 3 | R75P | – | +/+ | 0 | 1 | c | ||||
| 5 | 64/F | 224C>T | 3 | R75P | DL | IS | +/+ | Lt. CR | 16 | B,C,E | 3 | b1,c | |
| 6 | 57/F | 224G>A | 3 | R75Q* | HTN, DM, DL | IS | +/+ | Lt. thalamus | 9 | A,B,E | 2 | c | |
| 7 | 34/F | 328C>T | 3 | R110C | – | +/+ | 0 | 2 | a1,b1,c | ||||
| 8 | 44/M | 368G>A | 4 | C123Y | IS | +/+ | CR | 14 | C,D,E | 3 | a2, b1,c | ||
| 9 | 59/M | 505C>T | 4 | R169C | IS | +/+ | Cerebellum | 4 | B | 3 | a2,b2,c | ||
| 10 | 57/F | 544C>T | 4 | R182C | HTN | IS | +/+ | Lt. BG | 3 | B | 3 | a2,b2,c | |
| 11 | 62/F | 554G>A | 4 | C185Y | migraine | +/+ | 3 | a2,b2,c | |||||
| 12 | 62/F | 634T>G | 4 | C212G* | HTN | IS, migraine | +/+ | Lt. CR | 0 | 2 | a2, b1,c | ||
| 13 | 49/M | 778T>G | 5 | C260G | HTN, DL, SM | IS | +/+ | Rt. CR | 0 | 2 | a2,c | ||
| 14 | 60/F | 832T>C | 6 | C278R* | DL | IS | +/+ | pons | 24 | B,C,E | 3 | a2,b2,c | |
| 15 | 51/F | 1378G>T | 8 | G460C* | HTN | migraine | +/+ | 15 | A,B,C,D,E | 2 | a2, b1,c | ||
| 16 | 44/F | 1378G>T | 8 | G460C* | HTN, DL | migraine | +/+ | 0 | 2 | b1,c | |||
| 17 | 52/F | 1394A>G | 9 | Y465C | HTN | – | +/+ | 2 | B,E | 3 | b1,c | ||
| 18 | 30/F | 1394A>G | 9 | Y465C | migraine | −/− | N/A | N/A | N/A | N/A | N/A | N/A | |
| 19 | 52/F | 1394A>G | 9 | Y465C | DM | – | +/+ | 0 | 3 | c | |||
| 20 | 46/M | 1394A>G | 9 | Y465C | HS | +/+ | Lt. thalamus | 0 | 1 | c | |||
| 21 | 52/M | 160C>T | 11 | R54C | HTN | IS, HS | +/+ | Lt. pons | Lt. BG | 23 | B,C,D,E | 3 | a2,b2,c |
| 22 | 49/F | 160C>T | 11 | R54C | migraine | +/+ | 0 | 3 | a2,b2,c | ||||
| 23 | 70/F | 1624T>C | 11 | C542R* | IS, migraine | +/+ | Rt. thalamus | 11 | B,C,D,E | 3 | a2,b2,c | ||
| 24 | 50/F | 1624T>C | 11 | C542R* | – | +/− | N/A | N/A | N/A | N/A | |||
| 25 | 60/F | 1630C>T | 11 | R544C | – | +/+ | 0 | 2 | c | ||||
| 26 | 55/M | 1630C>T | 11 | R544C | HTN | migraine | −/− | N/A | N/A | N/A | N/A | N/A | c |
| 27 | 43/F | 1630C>T | 11 | R544C | DL | – (MMD) | +/+ | 1 | B | 1 | c | ||
| 28 | 62/F | 1630C>T | 11 | R544C | IS | +/+ | Lt.thalamus | 10 | B,E | 2 | a1,b1,c | ||
| 29 | 64/M | 1759C>T | 11 | R587C | HS | +/+ | Lt. thalamus | 2 | E | 2 | c | ||
| 30 | 55/M | 3182G>A | 20 | C1061Y | HTN, DL | IS | +/+ | Rt. MCA | 41 | A,B,C,D,E | 3 | a2,b2,c | |
| 31 | 53/M | 3226C>T | 20 | R1075C* | – | +/+ | 6 | B,E | 3 | a1,b2,c | |||
| 32 | 68/M | 3523C>T | 22 | R1175W* | HTN, DL, SM | – | +/+ | 0 | 3 | a2,b2,c | |||
| 33 | 46/F | 3523C>T | 22 | R1175W* | HTN, DM, DL | IS, HS | +/+ | Lt. MCA | Lt. CR | 0 | 1 | – | |
| 34 | 35/F | 3523C>T | 22 | R1175W* | HS, (MMD) | +/+ | Lt. BG | 0 | 0 | – |
Location of MBs: A, Basal ganglia; B, thalamus; C, cerebellum; D, brainstem; E, subcortex. White matter lesions: a1, anterior temporal lobe, unilateral; a2, anterior temporal lobe, bilateral; b1, external capsule, unilateral; b2, external capsule, bilateral; c, periventricular white matters. * Novel variants of unknown significance. † Three patients (number 17–19) are one family. Patient No. 18 was a daughter of patient No.17 and patient No. 19 was a sister of patient No.17. Patient No. 26 did not have brain MRI images, and MRI results from other hospitals were available only on chart records. Abbreviations: DL, dyslipidemia; HTN, hypertension; DM, diabetes mellitus; SM, smoking; IS, ischemic stroke; HS, hemorrhagic stroke; MMD, moyamoya disease; Rt, right; Lt, left; MCA, middle cerebral artery; CR, corona radiata; BG, basal ganglia; N/A, not applicable; MBs, microbleeds; MRI, magnetic resonance image.
Figure 2Anterior temporal pole involvement according to specific exon locations.
Figure 3Anterior temporal pole involvement in prevalent NOTCH3 mutations compared to mutations in Exon 4. (A) NOTCH3 gene mutations of R75P, Y465C, R544C, and R1175W variants of unknown significance (VUS) and (B) NOTCH3 gene mutations in exon 4 (C123Y, R169C, R182C, and C185Y).
Comparison of the different spectrum of NOTCH3, MRI features, and clinical presentations of cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL).
| Study | Race | Number of Patients | Age of Onset (± SD) | Mutation of NOTCH3 | MRI Features | Clinical Presentations | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| Stroke | Cognitive Impairment | Psychiatric Syndrome | Headaches | Seizures | ||||||
| This study | Korean | 34 | 52.5 ± 9.5 | Exon 2–6: 41.2% | AT: 50% | IS: 44.1% | Not specified | 0 | 2.5% | 0 |
| Markus et al., 2002 [ | British | 48 | 35.9 ± 14.6 | Exon 2–6: 93.8% | AT:89% | IS: 29.2% | 2.1% | 8.3% | 54.2% | 4.2% |
| Desmond et al., 1999 [ | American | 105 | 36.7 ± 12.9 | Not specified | Not specified | IS: 42.9% | 5.7% | 8.6% | 40% | 2.9% |
| Dotti et al., 2005 [ | Italian | 28 | Not specified | Exon 2–6: 46.42% | Not specified | Not specified | Not specified | Not specified | Not specified | Not specified |
| Lee et al., 2009 [ | Han Chinese in Taiwan | 21 | 48.6 ± 13.8 | Exon 2–6: 28.6% | AT: 42% | IS: 52.4% | 4.8% | 9.5% | 4.8% | 4.8% |
| Liu et al., 2015 [ | Chinese mainland | 62 | 39.7 ± 8.03 | Exon 4: 59.6% | AT: 63.5%* | IS or TIA: 75.8% | 11.3% | 3.2% | 8.1% | Not specified |
| Choi et al., 2006 [ | Korean | 20 | 57.2 ± 10.2 | Exon 2–6 (R75P): 10% | AT: 20% | IS: 55% | 15% | 0 | 10% | 0 |
| Choi et al., 2013 [ | Korean | 73 | 62.7 ± 11.1 | Exon 2–6 (R75P): 2.7% | Not specified | IS: 42.5% | Not specified | Not specified | Not specified | Not specified |
| Kim et al., 2006 [ | Korean | 27 | 47.7 | Exon 2–6: 77.8% | AT: 22.2% | IS: 40.7% | 18.5% | Depression 14.8% | 3.7% | 0 |
| Ueda et al., 2015 [ | Japanese | 70 | Patients with R75P: 53.6 ± 6.9 | Exon 3: 21% | AT: 70.6%† | IS or TIA: 69% | 31% | 20% | 33% | Not specified |
Abbreviations: SD, standard deviation; AT, anterior temporal; EC, external capsular; IS, ischemic; ICH, intracerebral hemorrhage. * Frequency was calculated among 52 patients with CADASIL Scale scores. † Frequency was calculated among 51 CADASIL patients with available MRI data.
Figure 4‘Founder effect’ reported in many countries.